Qualigen Therapeutics Faces Nasdaq Delisting Warning
Ticker: AIXC · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1460702
Sentiment: bearish
Topics: delisting-warning, compliance, nasdaq
TL;DR
Qualigen's stock is below $1, Nasdaq's giving them 6 months to fix it or get booted.
AI Summary
Qualigen Therapeutics, Inc. received a notification on October 18, 2024, indicating it is not in compliance with Nasdaq's minimum bid price requirement. The company has 180 days, until April 15, 2025, to regain compliance by increasing its closing bid price to $1.00 per share.
Why It Matters
Failure to meet the minimum bid price requirement could lead to the delisting of Qualigen's stock from Nasdaq, potentially impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company is at high risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement within the specified timeframe.
Key Numbers
- $1.00 — Minimum Bid Price (Required to remain listed on Nasdaq)
- 180 days — Compliance Period (Timeframe to regain compliance)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Nasdaq (company) — Listing Exchange
- October 18, 2024 (date) — Date of notification
- April 15, 2025 (date) — Deadline for compliance
- $1.00 (dollar_amount) — Minimum bid price requirement
FAQ
What is the specific reason Qualigen Therapeutics received a delisting warning?
Qualigen Therapeutics received the warning because its closing bid price has fallen below the $1.00 minimum requirement for continued listing on the Nasdaq Capital Market.
What is the deadline for Qualigen Therapeutics to regain compliance with Nasdaq's listing rules?
The company has until April 15, 2025, which is 180 calendar days from the date of the notification (October 18, 2024), to meet the minimum bid price requirement.
What actions can Qualigen Therapeutics take to regain compliance?
The company must increase its closing bid price to $1.00 or more per share for a minimum of ten consecutive business days during the 180-day compliance period.
What happens if Qualigen Therapeutics fails to regain compliance?
If the company does not regain compliance by April 15, 2025, Nasdaq will initiate delisting procedures for its common stock.
Has Qualigen Therapeutics previously faced similar listing issues?
The filing does not explicitly state if the company has faced similar issues before, but it does mention that the notification is pursuant to Nasdaq Listing Rule 5550(a)(2).
Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-10-22 16:35:38
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-24-042068.txt ( ) — 205KB
- qlgn-20241018.xsd (EX-101.SCH) — 3KB
- qlgn-20241018_lab.xml (EX-101.LAB) — 33KB
- qlgn-20241018_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: October 22, 2024 By: /s/ Kevin Richardson II Kevin Richardson II, Interim Chief Executive Officer